BridgeMD
New treatment option for Obesity
Official title Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
ClinicalTrials.gov ID: NCT07513168
What this study is testing
What is Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)?
Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg) is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for obesity.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes mellitus. The study will be conducted at the Asian Institute of Medical Sciences (AIMS), Hyderabad, Sindh, Pakistan.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged 18 years or older.
- Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs.
- No diagnosis of type 2 diabetes mellitus, confirmed by: Fasting blood glucose \< 126 mg/dL, and HbA1c \< 6.5% within three months prior to enrollment.
- Willingness and ability to provide written informed consent.
- Willingness to comply with study procedures, including weekly injections and lifestyle counseling.
You likely can't join if
- History of pancreatitis.
- History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
- Pregnant or lactating women.
- Severe renal impairment (eGFR \ 3× upper limit of normal).
- Current use of other anti-obesity medications.
- Known hypersensitivity to semaglutide or any component of the formulation.
See the full eligibility criteria
- Adults aged 18 years or older.
- Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs.
- No diagnosis of type 2 diabetes mellitus, confirmed by: Fasting blood glucose \< 126 mg/dL, and HbA1c \< 6.5% within three months prior to enrollment.
- Willingness and ability to provide written informed consent.
- Willingness to comply with study procedures, including weekly injections and lifestyle counseling.
- History of pancreatitis.
- History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
- Pregnant or lactating women.
- Severe renal impairment (eGFR \ 3× upper limit of normal).
- Current use of other anti-obesity medications.
- Known hypersensitivity to semaglutide or any component of the formulation.
- Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Hyderābād, Sindh, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hyderābād, Sindh, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.